Originally published at: In-Silico Antibody Development with AlphaBind Using NVIDIA BioNeMo and AWS HealthOmics | NVIDIA Technical Blog
Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range of diseases, from cancer to autoimmune disorders. Their specificity reduces the likelihood of off-target effects, making them safer and often more effective than small-molecule drugs for complex conditions. As a…